This post was originally published on this site
A research group leader at Oxford, Sandy Douglas, told FT that preliminary steps in producing an updated vaccine have been taken in case it is needed, together with their partners AstraZeneca.
“Adenovirus-based vaccines (such as that made by Oxford/AstraZeneca) could in principle be used to respond to any new variant more rapidly than some may previously have realised,” Douglas added.
AstraZeneca and Oxford did not immediately respond to requests for comment outside business hours.
